tradingkey.logo

tradingkey.logo
怜玢


MapLight Therapeutics Inc

MPLT
りォッチリストに远加
7.250USD
+0.180+2.55%
終倀 11-13 16:00ET
402.95M時䟡総額
損倱額盎近12ヶ月PER

MapLight Therapeutics Incに぀いお 䌁業名

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009.

MapLight Therapeutics Inc プロフィヌル


䌁業コヌド- -
䌚瀟名- -
䞊堎日- -
最高経営責任者「CEO」- -
埓業員数- -
蚌刞皮類- -
決算期末- -
本瀟所圚地- -
郜垂- -
蚌刞取匕所- -
囜- -
郵䟿番号- -
電話番号- -
りェブサむト- -
䌁業コヌド- -
䞊堎日- -
最高経営責任者「CEO」- -

MapLight Therapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Anatol Kreitzer, Ph.D.
Dr. Anatol Kreitzer, Ph.D.
Chief Discovery Officer
Chief Discovery Officer
168.68K
-7.26%
Mr. Jonathan Gillis, CPA
Mr. Jonathan Gillis, CPA
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
142.19K
-7.15%
Ms. Erin Pennock Foff, M.D., Ph.D.
Ms. Erin Pennock Foff, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
10.16K
-538.62%
Mr. Martin Babler
Mr. Martin Babler
Independent Director
Independent Director
7.86K
--
Mr. Troy M. Cox
Mr. Troy M. Cox
Independent Director
Independent Director
7.86K
--
Mr. Vishwas Setia
Mr. Vishwas Setia
Chief Financial Officer
Chief Financial Officer
68.00
-53486.76%
Mr. Robert Malenka, M.D., Ph.D.
Mr. Robert Malenka, M.D., Ph.D.
Director
Director
--
--
Dr. Christopher A. Kroeger, M.D.
Dr. Christopher A. Kroeger, M.D.
Co-Founder, President, Chief Executive Officer, Director
Co-Founder, President, Chief Executive Officer, Director
--
--
Mr. James Lillie, Ph.D.
Mr. James Lillie, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Kristopher L. Hanson
Mr. Kristopher L. Hanson
General Counsel
General Counsel
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Anatol Kreitzer, Ph.D.
Dr. Anatol Kreitzer, Ph.D.
Chief Discovery Officer
Chief Discovery Officer
168.68K
-7.26%
Mr. Jonathan Gillis, CPA
Mr. Jonathan Gillis, CPA
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
142.19K
-7.15%
Ms. Erin Pennock Foff, M.D., Ph.D.
Ms. Erin Pennock Foff, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
10.16K
-538.62%
Mr. Martin Babler
Mr. Martin Babler
Independent Director
Independent Director
7.86K
--
Mr. Troy M. Cox
Mr. Troy M. Cox
Independent Director
Independent Director
7.86K
--
Mr. Vishwas Setia
Mr. Vishwas Setia
Chief Financial Officer
Chief Financial Officer
68.00
-53486.76%

よくある質問

MapLight Therapeutics Incの䞊䜍5名の株䞻は誰ですか


MapLight Therapeutics Incの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Anatol Kreitzer, Ph.D.
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。